drugset / Trial / NCT06861088

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

NCT06861088

Phase 3 Recruiting 480 enrolled Quercis Pharma AG
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.

Timeline

Start
2025-12-19
Primary completion
2027-10-31
Completion
2029-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Isoquercetin Small molecule 1000 mg Oral
Subject Isoquercetin Small molecule 2000 mg Oral